Elixir Medical Corporation

Print Article


Elixir Medical Corporation to Showcase Results for the Fully Bioresorbable DESolve® Novolimus Eluting Coronary Scaffold Systems at EuroPCR 2015

Elixir Symposium with Key Thought Leaders Scheduled for May 19

Sunnyvale, CAMay 13, 2015—Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced today that it will showcase long-term imaging results of its CE Mark-approved DESolve® Novolimus Eluting Bioresorbable Coronary Scaffold Systems at EuroPCR in Paris. EuroPCR is the official annual meeting of the European Association for Percutaneous Cardiovascular Interventions.

A demonstration of the breakthrough DESolve® 100 Scaffold System will also be performed and streamed live by Dr. Alexandre Abizaid, MD, PhD, from his cardiac catheterization lab at Instituto Dante Pazzanese de Cardiologia in Sao Paulo, Brazil, for the Elixir Symposium audience in Theatre Havane on Tuesday, May 19.

Following are some of the highlights of Elixir Medical’s programs and activities at the EuroPCR conference (in chronological order) at the Palais Des Congres de Paris in Central European Summer Time (CEST):


Tuesday, May 19: 17:00 – 18:30, Theatre Havane

Elixir Medical Symposium

Transforming PCI with the DESolve® Novolimus Eluting Scaffold Platforms



 Live Case Demonstration from Sao Paulo, Brazil


Tuesday, May 19: 13:40 – 2:10, Room 343

DES: impact of biodegradable versus durable polymer on clinical outcomes

Multicentre, prospective, randomised, single-blind, consecutive enrolment evaluation of a novolimus-eluting coronary   stent system with bioabsorbable polymer compared to a zotarolimus-eluting coronary stent system: long-term (48-month) clinical follow-up

Wednesday, May 20: 08:15 – 9:15, Room 252A

Planned and ongoing clinical trials: a status update from genae

DESolve: novolimus-eluting bioresorbable coronary scaffold system Speaker Dr.

Wednesday, May 20: 14:40 – 15:40, Arlequin

Bioresorbable Scaffolds and new DES (Selected Abstract Sessions)

-          A new novolimus-eluting bioresorbable scaffold with a strut thickness of 100 µm: First clinical experience of an OCT evaluation in an all-comer population

-          Evaluation of PCI with everolimus-eluting versus novolimus-eluting bioresorbable scaffolds in an all-comer population: a matched analysis


Thursday, May 21: 9:20 – 10:20, Temes 2

            Bioresorbable Scaffolds: Insight from intracoronary imaging (Selected Cases)

BIOSOLVE-II case presentation with 6- and 12-moth imaging follow-up and DESolve implantation at 6 months:

Thursday, May 21: 10:30 – 12:00, Maillot

Bench testing and preclinical evaluation of a novolimus-eluting scaffold:


Friday, May 22: 11:45 – 12:45, Room 253

            OCT insights in current CE-marked bioresorbable scaffolds

Multicentre evaluation of the novolimus-eluting, fully bioresorbable coronary scaffold: 2-year clinical and longer-term imaging endpoints

ABSORB versus DESolve: An OCT study comparison of the acute mechanical performances

Elixir Medical will have a booth at EuroPCR:  Booth # F5, Second Floor. The booth will be open Tuesday, May 19 through Friday, May 22.


About Elixir Medical

Elixir Medical Corporation, a privately held company headquartered in Sunnyvale, California, develops products that combine state-of-the-art medical devices with advanced pharmaceuticals to provide innovative treatment solutions to patients worldwide. The company's next-generation drug-eluting stent systems and bioresorbable coronary scaffold are designed to optimize localized drug delivery to provide safe and effective treatments for cardiovascular patients. For more information, visit www.elixirmedical.com



Donna Collins 

Ph: (408) 636-2060